"The ongoing policy debate about pharmaceutical and biologic patents has been coopted by those who don't like patents-including those who have a financial incentive not to like patents. These paid mercenaries concoct and then disseminate fraudulent "reports", which have become the lifeblood for patent critics. Even when the inaccuracies and lies are clearly identified, the cacophony of patent haters drowns out the truth thanks to a complicit, ideologically aligned popular press that continues to cite and rely on fabricated "findings" that couldn't stand up to the scrutiny of your average fifth grader."
"Although not the only example by a longshot, the easiest, most clear example of fiction masquerading as truth comes to us courtesy of the Initiative for Medicines, Access & Knowledge (I-MAK), which the Council for Innovation Promotion (C4IP) has recently launched a campaign to expose. As recently as July 2023, I-MAK's website proclaimed there was "no generic alternative to Pfizer's drug Lyrica® approved by the Food and Drug Administration (FDA) or available on the market.""
"I-MAK's claim about Lyrica® is false. The FDA approved multiple generics of Lyrica® in July 2019, which coincided with the patent expiration of the Lyrica® compound patent in June 2019. And those generics were on the market well before I-MAK made this incorrect statement. What makes this example particularly egregious is I-MAK continued to pedal this phony claim long after it had been exposed as untrue. And Lyrica® is not the only drug for which I-MAK has made similarly false claims. I-MAK claimed patents on Revlimid® would prevent generic competition until at least 2028 despite Teva launching the first generic in 2022."
The policy debate over pharmaceutical and biologic patents has been infiltrated by anti-patent actors with financial incentives who produce and spread fraudulent reports. Paid groups fabricate and disseminate inaccurate claims that persist even after being debunked, helped by an ideologically aligned popular press. The Initiative for Medicines, Access & Knowledge (I-MAK) repeatedly asserted false statements about generic availability, including a claim in July 2023 that no generic Lyrica® existed despite FDA approvals and market entry in July 2019. I-MAK also made incorrect predictions about Revlimid® and Gleevec® generic competition that proved inaccurate.
Read at IPWatchdog.com | Patents & Intellectual Property Law
Unable to calculate read time
Collection
[
|
...
]